Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
OSTEOFORM, containing recombinant (rhPTH [1-34]), enhances bone mineral density and reduces
risk for vertebral fracture. This study evaluates the safety and efficacy of OSTEOFORM in the
treatment of osteoporosis in post-menopausal women.
Phase:
Phase 3
Details
Lead Sponsor:
Virchow Group
Treatments:
Calcium, Dietary Ergocalciferols Vitamin D Vitamins